Free tool
FAERS Monitor: Cardizem La
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021392 or its brand name (Cardizem La, Diltiazem Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
12,237
Serious
10,144
83% of reports
Hospitalization
5,561
Death reported
2,820
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,394
- pain1,244
- fatigue1,212
- fall1,078
- diarrhoea949
- arthralgia940
- headache938
- dizziness930
- nausea914
- pruritus887
- drug ineffective886
- hypotension856
- pyrexia852
- off label use826
- hypersensitivity756
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 398 |
| 2005 | 412 |
| 2006 | 264 |
| 2007 | 193 |
| 2008 | 207 |
| 2009 | 201 |
| 2010 | 243 |
| 2011 | 224 |
| 2012 | 344 |
| 2013 | 306 |
| 2014 | 248 |
| 2015 | 299 |
| 2016 | 358 |
| 2017 | 353 |
| 2018 | 358 |
| 2019 | 390 |
| 2020 | 541 |
| 2021 | 895 |
| 2022 | 1,440 |
| 2023 | 1,117 |
| 2024 | 1,353 |
| 2025 | 1,308 |
| 2026 | 785 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypotensionSignal | 856 | 7.4 | 6.9 | 4,725 |
| hypersensitivitySignal | 756 | 7.0 | 6.6 | 3,919 |
| fallSignal | 1,078 | 5.6 | 5.3 | 4,102 |
| dyspnoeaSignal | 1,394 | 4.2 | 4.0 | 3,535 |
| pyrexiaSignal | 852 | 4.2 | 4.0 | 2,136 |
| pruritusSignal | 887 | 4.0 | 3.7 | 2,003 |
| arthralgiaSignal | 940 | 3.9 | 3.7 | 2,053 |
| painSignal | 1,244 | 3.5 | 3.3 | 2,264 |
| dizzinessSignal | 930 | 3.2 | 3.0 | 1,444 |
| fatigueSignal | 1,212 | 2.7 | 2.5 | 1,320 |
| headacheSignal | 938 | 2.6 | 2.4 | 927 |
| diarrhoeaSignal | 949 | 2.5 | 2.4 | 902 |
| nausea | 914 | 2.0 | 1.9 | 463 |
| off label use | 826 | 1.6 | 1.5 | 205 |
| drug ineffective | 886 | 1.2 | 1.1 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.